𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2

✍ Scribed by Dr. Lois M. Mulligan; Emily Gardner; Barbara A. Smith; Chris G. P. Mathew; Bruce A. J. Ponder


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
928 KB
Volume
6
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Multiple endocrine neoplasia type 2 (MEN 2) is a familial cancer syndrome arising from mutation at a locus or loci in chromosome region 10p11.2‐q11.2. The disease is characterized by medullary thyroid carcinoma (MTC) and pheochromocytoma (Pheo). To assess the genetic events in tumour initiation and progression in this disease, we have compiled an allelotype for MTC and Pheo tumours using polymorphic marker loci from each chromosome arm. Using a panel of 58 tumours, we found frequent allele losses on chromosome arms 1p (42%), 3p (30%), 3q (38%), 11p (11%), 13q (10%), 17p (8%), and 22q (29%). Loss of heterozygosity (LOH) for loci on chromosome 10 was detected in a single tumour where one whole chromosome copy was lost. We used a panel of polymorphic markers for each of chromosomes 1, 3, 11, and 17 to define a shortest region of overlap for these regions. The most frequent allele losses were on chromosome 1, spanning the entire short arm of the chromosome but not loci on 1q. LOH on chromosome 3 encompassed a minimal common region of 3q12‐qter. The regions of allelic deletion on chromosome 11(11pter‐p13), 17(17pter‐p11.2), and 13 (13q) encompass known tumour suppressor loci (WTI, TP53, RBI) which must therefore be candidates for genes contributing to MTC and Pheo development. Our data suggest allele loss on chromosome 11, 13, or 17 occurs predominantly in tumours with losses on chromosome 3, potentially reflecting the accumulation of genetic change in tumour progression. These events may be associated with more advanced disease in MTC. We suggest that at least 7 genes contribute to tumour development in MEN 2, including an initiating locus on chromosome 10 and loci on chromosomes 1, 3, 11, 13, 17, and 22 which have a progressional role in these tumours. Β© 1993 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Bronchopulmonary carcinoid in multiple e
✍ Nirupa Sachithanandan; Robin A. Harle; John R. Burgess πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 82 KB

## Abstract ## BACKGROUND Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal‐dominant syndrome associated with neoplasia of pituitary, pancreas, parathyroid, and foregut lineage neuroendocrine tissue. Although enteropancreatic carcinoid has been well described in patients with MEN 1, it w

Genetic events and the role of TGFΞ² in e
✍ Akhurst, Rosemary J.; Balmain, Allan πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 290 KB πŸ‘ 1 views

The mouse skin model of chemical carcinogenesis has been very well characterized with respect to epigenetic changes, which occur during tumour cell initiation, promotion and progression. The use of transgenic and gene knock-out mice has contributed greatly to knowledge in this area. The H-ras geneti

Mutations of the RET proto-oncogene in t
✍ Charis Eng; Lois M. Mulligan πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 225 KB πŸ‘ 2 views

## Communicated by Martin Bobrow The RET proto-oncogene codes for a receptor tyrosine kinase thought to play a role in the development of neural crest and its derivatives. Mutations in the RET proto-oncogene have been found in patients with the multiple endocrine neoplasia type 2 syndromes (MEN 2)